Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802103 | 0.84 | DHFR (0.38) | DHFRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL28150295 | 0.84 | DHFR (0.44) | DHFRHSP90AA1NUDT1PKMTLR8 | |
| SCHEMBL15579444 | 0.82 | DHFR (0.43) | DHFRHSP90AA1NUDT1KDM4EMEN1 | |
| SCHEMBL28236618 | 0.82 | DHFR (0.47) | DHFRNUDT1PKM | |
| SCHEMBL28902641 | 0.81 | DHFR (0.36) | DHFRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL10399566 | 0.78 | NUDT1 (0.43) | DHFRHSP90AA1NUDT1MEN1ALDH1A1 | |
| SCHEMBL28762999 | 0.77 | HSP90AA1 (0.56) | DHFRHSP90AA1NUDT1KDM4EMEN1 | |
| SCHEMBL27523630 | 0.76 | DHFR (0.48) | DHFR | |
| SCHEMBL28874972 | 0.75 | HSP90AA1 (0.41) | DHFRHSP90AA1NUDT1PKML3MBTL1 | |
| SCHEMBL1554275 | 0.74 | PKM (0.55) | DHFRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113966326-A | Water soluble adjuvants | 大日本住友制药株式会社 | 2022-01-21 | — | — | CN | disclosed |
| US-20090074886-A1 | GSK-3 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2009-03-19 | — | — | US | disclosed |
| EP-1653970-A4 | GSK-3 INHIBITORS AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1653970-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| WO-2005039485-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050054663-A1 | Bone disorders; osteoporosis | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0504180-B1 | GLYCYL-P-AMINO-PYRIDINE FOR THE TREATMENT OF SENILE DEMENTIA STATES | MEDEA RES SRL (IT) | 1993-10-27 | — | — | EP | disclosed |
| US-5244897-A | GLYCYL-P-AMINO-PYRIDINE FOR THE TREATMENT OF SENILE DEMENTIA STATES | MEDEA RESEARCH S.R.L. (IT) | 1993-09-14 | — | — | US | disclosed |
| EP-0504180-A1 | GLYCYL-P-AMINO-PYRIDINE FOR THE TREATMENT OF SENILE DEMENTIA STATES. | MEDEA RES SRL (IT) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991007963-A1 | GLYCYL-P-AMINO-PYRIDINE FOR THE TREATMENT OF SENILE DEMENTIA STATES | MEDEA RESEARCH S.R.L. (IT) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054663-A1 | Bone disorders; osteoporosis | GSK3B, GSK3A, GSKIP | DHFR 1600/4885HSP90AA1 4117/4885NUDT1 454/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | DHFR 1042/4885HSP90AA1 1343/4885NUDT1 2465/4885 |
| US-20090074886-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | DHFR 1638/4885HSP90AA1 3567/4885NUDT1 1100/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | DHFR 1042/4885HSP90AA1 1343/4885NUDT1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.